Premium
Hepatitis C reinfection with protease inhibitor‐resistant hepatitis C virus in an HIV‐coinfected MSM
Author(s) -
Yilmaz Gül R.,
Boesecke Christoph,
SchwarzeZander Carolynne,
Rockstroh Jürgen K.
Publication year - 2020
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.14275
Subject(s) - virology , hepatitis c virus , medicine , men who have sex with men , protease inhibitor (pharmacology) , hepatitis c , transmission (telecommunications) , human immunodeficiency virus (hiv) , virus , immunology , viral load , antiretroviral therapy , syphilis , electrical engineering , engineering
There is an ongoing global hepatitis C virus (HCV) epidemic mainly related to high‐risk behaviour in persons who inject drugs (PWID) and in HIV‐infected men who have sex with men (MSM) which continues to fuel the HCV epidemic. Treatment of HCV infection with direct antiviral therapy (DAA) has been very successful in the last decade. Main obstacles for HCV elimination are HCV reinfections observed in PWID and HIV‐infected MSM. We present here an HIV‐infected MSM patient who has been reinfected thrice with HCV. The virus which was investigated from his last reinfection episode reveals transmission of a newly acquired HCV protease inhibitor (PI) resistance, despite not having been exposed to HCV‐PIs during his last DAA therapy.